RxDoctor Payments Data

Wei Liu, MD

Internal Medicine · Flushing, NYNPI 1902251804

Payments from drug & device makers

$6,392in general payments, 2019–2025

Across 228 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$759
  • Amgen$731
  • AstraZeneca$610
  • Lilly USA, LLC$492
  • Gilead$489
  • Bayer$443
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$6,384100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,392 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$24,282
Medicare patients
34
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl232$93,660
Diclofenac Epolamine103$73,974
JanuviaSitagliptin Phosphate47$57,490
ProliaDenosumab19$32,564
FarxigaDapagliflozin Propanediol36$31,849
JardianceEmpagliflozin28$28,754
RybelsusSemaglutide13$27,513
EliquisApixaban19$26,268
JanumetSitagliptin Phos/Metformin Hcl35$25,602
XareltoRivaroxaban24$24,949
VemlidyTenofovir Alafenamide13$21,030
OzempicSemaglutide16$17,914
Diclofenac Sodium53$13,712
RestasisCyclosporine22$13,503
LinzessLinaclotide21$10,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Belsomra$207$88,85695 claims
Novo NordiskRybelsus, Ozempic$759$45,42729 claims
AstraZenecaFarxiga, Symbicort$610$34,54947 claims
AmgenProlia$731$32,56419 claims
Boehringer IngelheimJardiance$90$28,75428 claims
AbbVieRestasis, Linzess$394$24,26343 claims
GileadVemlidy$489$21,03013 claims
GSKShingrix$302$3,30817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →